Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences Inc.

< Previous 1 2 3 Next >
Castle Biosciences Reports Second Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Honored with Top Workplaces Awards
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports First Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Updates to its Board of Directors
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.